CompletedNot Applicable

Surgery Benefits Takayasu Arteritis With Stenosis in the Descending Aorta

78 participantsStarted 2004-01-01

Plain-language summary

The long-term prognosis and optimal management for Takayasu arteritis(TA) patients with severe stenosis of the descending thoracic and abdominal aorta remain undefined. We want to compare the clinical outcomes of surgical intervention and medical management.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. fulfilling the 1990 American College of Rheumatology criteria for the diagnosis of TA;
. having at least one site with severe narrowing in the descending thoracic and abdominal aorta;
. having symptoms caused by TA-related stenosis, such as uncontrolled hypertension, heart failure, renal ischemia, dizziness, visual disturbances, and claudication

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

all-cause mortality rate

Timeframe: Patients underwent follow-up from discharge until study termination (3 years to 11 years) or death, whichever came first

all-cause mortality rate

Timeframe: Patients underwent follow-up from discharge (3 years to 11 years) until study termination or death, whichever came first

Trial details

NCT IDNCT07149805

SponsorPeking Union Medical College Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-01-01

View on ClinicalTrials.gov More Takayasu Arteritis trials

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. fulfilling the 1990 American College of Rheumatology criteria for the diagnosis of TA;
. having at least one site with severe narrowing in the descending thoracic and abdominal aorta;
. having symptoms caused by TA-related stenosis, such as uncontrolled hypertension, heart failure, renal ischemia, dizziness, visual disturbances, and claudication

What they're measuring

all-cause mortality rate

Timeframe: Patients underwent follow-up from discharge until study termination (3 years to 11 years) or death, whichever came first

all-cause mortality rate

Timeframe: Patients underwent follow-up from discharge (3 years to 11 years) until study termination or death, whichever came first